↓ Skip to main content

Efficacy and Safety of Thalidomide As a Pre-Medication of Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy (HEC): A Systematic Review and Meta-Analysis

Overview of attention for article published in Frontiers in oncology, January 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and Safety of Thalidomide As a Pre-Medication of Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy (HEC): A Systematic Review and Meta-Analysis
Published in
Frontiers in oncology, January 2022
DOI 10.3389/fonc.2021.818839
Pubmed ID
Authors

Jiyi Xie, Cong Zhang, Shijun Li, Rong Dai, Mitchell A. Sullivan, Bin Deng, Qiling Xu, Jinglin Wang, Chen Shi, Yu Zhang

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 27%
Student > Ph. D. Student 2 18%
Professor > Associate Professor 1 9%
Unspecified 1 9%
Unknown 4 36%
Readers by discipline Count As %
Nursing and Health Professions 2 18%
Pharmacology, Toxicology and Pharmaceutical Science 2 18%
Medicine and Dentistry 2 18%
Unspecified 1 9%
Engineering 1 9%
Other 0 0%
Unknown 3 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2022.
All research outputs
#22,774,430
of 25,392,582 outputs
Outputs from Frontiers in oncology
#15,927
of 22,436 outputs
Outputs of similar age
#441,740
of 517,326 outputs
Outputs of similar age from Frontiers in oncology
#896
of 1,431 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,436 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 517,326 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,431 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.